Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

121.17
+0.29000.24%
Volume:31.64K
Turnover:3.82M
Market Cap:546.48M
PE:6.28
High:121.18
Open:120.78
Low:120.17
Close:120.88
52wk High:131.68
52wk Low:92.10
Shares:4.51M
Float Shares:4.51M
Volume Ratio:0.83
T/O Rate:0.70%
Dividend:1.12
Dividend Rate:0.93%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.57

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
Oct 02

AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval

Simply Wall St.
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

TIPRANKS
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall

Dow Jones
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

AbbVie Says Phase 3 Trials Show Rinvoq Vitiligo Repigmentation Gains Extend to Week 76

Reuters
·
Oct 01

Abbvie - Phase 3 Studies Show Continued Repigmentation with Rinvoq Through Week 76

THOMSON REUTERS
·
Oct 01

Abbvie - Rinvoq Plus NB-Uvb Shows Higher Repigmentation than Rinvoq Alone

THOMSON REUTERS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

AbbVie to Host Third-Quarter 2026 Earnings Call Webcast

Reuters
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Oct 01

Coty Names Kara Langan General Manager, U.S. Consumer Beauty Division

Reuters
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow

Simply Wall St.
·
Oct 01